Pediatric Invasive Pneumococcal Disease in Guatemala City: Importance of Serotype 2. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Gaensbauer, James T.; Asturias, Edwin J.; Soto, Monica; Holt, Elizabeth; Olson, Daniel; Halsey, Neal A.
• Is Part Of: Pediatric infectious disease journal. Volume 35:Issue 5(2016)
• Publication Date: 2016-05
• Subjects: bacterial meningitis -- pneumonia -- Guatemala -- pneumococcus -- serotype; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000001067
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Introduction: To inform estimations of the potential impact of recently introduced pneumococcal conjugate vaccine (PCV), we report results of 11 years of pre-PCV surveillance for invasive pneumococcal disease (IPD) among children in Guatemala City. Methods: Cases of IPD in children younger than 5 years were identified by active surveillance at 3 referral hospitals in Guatemala City from October 1996 through 2007. Clinical and demographic data were obtained, and isolates of Streptococcus pneumoniae from normally sterile sites were serotyped using latex agglutination and confirmed by Quellung reaction. Results: Four hundred fifty-two cases of IPD were identified with a case fatality rate of 21%. Meningitis was the most common cause of death (77% of all deaths) and occurred more often in infancy (median age 5 months) than other clinical syndromes. Of the 137 isolates serotyped, type 1 (26 cases, 17%), type 2 (25 cases, 16%) and type 5 (18 cases, 12%) were the most common. Serotype 2 was associated with a higher case fatality rate (28%), higher rate of meningitis (68%) and occurred in younger infants (median age, 3.5 months) than other common serotypes. Recently introduced PCV13 includes 73% of observed serotypes in the study. Conclusion: Infants with IPD presented at a young age. Serotype 2, rarely reported as a significant cause of IPD and not included in available PCVs, was a common cause of disease in this population. PCV13 introduction in Guatemala, begun in 2013, may not have as great an impact in disease reduction as has been observed in other countries.